Amphastar Pharmaceuticals AMPH Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $79.23M-19.2% | $98.09M-12.1% | $111.63M-17.1% | $134.71M-4.9% | $141.63M-11.2% | ||
| $32.36M+2.2% | $31.65M+2.6% | $30.83M+2.1% | $30.19M+4.8% | $28.8M+2.0% | ||
| $28.16M+3.2% | $27.28M+2.1% | $26.7M+2.7% | $26M+2.4% | $25.4M+4.2% | ||
| $3.35M0.0% | $3.36M+4.4% | $3.21M+4.6% | $3.07M-34.2% | $4.67M-22.6% | ||
| -$41K-5.1% | -$39K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $67.71M-3.2% | $69.91M+43.3% | ||
| -$12.56M-176% | -$4.56M-111% | $40.2M+1.7% | $39.51M-32.0% | $58.09M-8.6% | ||
| —— | —— | $13.6M-17.0% | $16.38M+43.9% | $11.38M+6.1% | ||
| $25.08M+0.1% | $25.05M+0.4% | $24.96M+0.4% | $24.87M+0.3% | $24.79M+0.3% | ||
| $7.05M+8.4% | $6.51M+6.9% | $6.09M+11.1% | $5.48M+12.9% | $4.86M+14.6% | ||
| $168.88M+8.2% | $156.12M+2.5% | $152.28M-4.6% | $159.66M-17.4% | $193.17M-9.5% | ||
| $33.69M-3.4% | $34.88M-10.6% | $39.02M-17.8% | $47.47M+10.5% | $42.95M+4.6% | ||
| -$97.55M-38.7% | -$70.33M-54.8% | -$45.44M+24.8% | -$60.41M+53.4% | -$129.69M-3.8% | ||
| $94.08M+24.5% | $75.59M-22.1% | $97.07M-23.7% | $127.18M— | —— | ||
| —— | —— | —— | —— | —— | ||
| $214K-4.0% | $223K-4.7% | $234K+1.3% | $231K-97.2% | $8.2M-0.7% | ||
| —— | $687K— | —— | —— | —— | ||
| -$83.13M-23.3% | -$67.43M+18.7% | -$82.89M+18.2% | -$101.36M-23.8% | -$81.88M-1.1% | ||
| —— | —— | —— | $186K+644% | $25K+113% | ||
| —— | —— | —— | —— | —— | ||
| $22.93M-1.2% | $23.22M-1.4% | $23.56M-4.3% | $24.62M-4.4% | $25.76M-3.9% | ||
| $19.5M-14.1% | $22.71M-32.0% | $33.41M-26.5% | $45.47M+17.0% | $38.85M-3.1% | ||
| —— | —— | —— | —— | —— | ||
| $25.08M+0.1% | $25.05M+0.4% | $24.96M+0.4% | $24.87M+0.3% | $24.79M+0.3% | ||
| $32.36M+2.2% | $31.65M+2.6% | $30.83M+2.1% | $30.19M+4.8% | $28.8M+2.0% | ||
| -$41K-5.1% | -$39K— | —— | —— | —— | ||
| —— | —— | —— | $1.4M+115% | -$9.31M-36.3% | ||
| —— | —— | $13.6M-17.0% | $16.38M+43.9% | $11.38M+6.1% | ||
| $7.05M+8.4% | $6.51M+6.9% | $6.09M+11.1% | $5.48M+12.9% | $4.86M+14.6% | ||
| -$6.27M-11.8% | -$5.61M-16.0% | -$4.84M-14.8% | -$4.21M-18.5% | -$3.56M+5.1% | ||
| —— | $687K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $4.28M-1.9% | $4.36M-19.1% | $5.39M+11.0% | $4.86M+52.9% | $3.18M-22.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $135.19M+11.5% | $121.23M+7.0% | $113.26M+1.0% | $112.19M-25.3% | $150.23M-12.8% | ||
| $135.19M+11.5% | $121.23M+7.0% | $113.26M+1.0% | $112.19M-25.3% | $150.23M-12.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amphastar Pharmaceuticals generate?
- Amphastar Pharmaceuticals (AMPH) generated $168.9M in operating cash flow over the trailing twelve months.
- What is Amphastar Pharmaceuticals's free cash flow?
- After $33.7M of capital expenditures, Amphastar Pharmaceuticals's free cash flow was $135.2M over the trailing twelve months, down 10.0% year over year.
- Where does Amphastar Pharmaceuticals's cash flow data come from?
- Every line is extracted from Amphastar Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
